Glioblastoma Expert Calls for Changes to Clinical Trial DesignDecember 11th 2018
Failed clinical trials in glioblastoma are hampering the path toward novel treatment regimens in this difficult-to-treat malignancy and old approaches to clinical trial design are reducing the appetite for involvement, according to Erik P. Sulman, MD, PhD.
Phase I Study Considers Potential for Personalized Immunotherapy in GlioblastomaNovember 11th 2018
A peptide-based personalized vaccine demonstrated encouraging signals of efficacy and was well tolerated in patients with newly diagnosed glioblastoma, according to the results of the phase I GAPVAC-101 trial.
Despite Advances, Interpreting Data From Genomics and Precision Medicine LagsOctober 25th 2018
I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Financial Advocacy Grows Under the Value-Based SystemOctober 24th 2018
Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
ACCC President Reignites Resilience in Oncology CaregiversOctober 23rd 2018
Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid TumorsOctober 22nd 2018
Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?October 19th 2018
Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
First Patient Dosed in Phase I/II Trial of Novel Immunotherapy Combination in Newly Diagnosed GlioblastomaJuly 9th 2018
The first patient has been dosed in a phase I/II open-label, multicenter trial investigating a novel immunotherapy combination in patients with newly diagnosed glioblastoma. Fifty patients have been accrued in the trial, as of May 31, 2018, which will be conducted at 25 sites across the nation.
Regorafenib Doubles 12-Month Survival Compared with Lomustine in Recurrent GBMJune 28th 2018
Regorafenib (Stivarga) improved overall survival and progression-free survival compared with lomustine (Gleostine) for patients with glioblastoma that recurred following surgery and treatment with the Stupp regimen, according to updated results presented in a poster at the 2018 ASCO Annual Meeting.